2022 American Transplant Congress
Nivolumab After Sorafenib Failure in Liver Recipients with HCC Recurrence
Surgery, Samsung Medical Center, Seoul, Korea, Republic of
*Purpose: Several treatments have recently been known for hepatocellcular carcinoma (HCC) who have failed to treat sorafenib. Immune checkpoint inhibitors have proven to be effective,…2022 American Transplant Congress
Characterizing Outcomes of Patients with Colorectal Liver Metastases (CRLM) Undergoing Liver Transplantation (LT) Evaluation
*Purpose: LT is a novel therapy for patients with unresectable CRLM. 5 year survival using LT appears to be significantly better than systemic chemotherapy in…2022 American Transplant Congress
Frequency of Cervical Cancer Screening in Solid Organ Transplant Recipients
*Purpose: Human papillomavirus-related anogenital malignancies disproportionately affect solid organ transplant recipients (SOTR) compared to the general population. Proposed cervical Pap testing intervals for SOTR differ…2022 American Transplant Congress
Liver Transplantation for Combined Hepatocellular-Cholangiocarcinoma: An Analysis of the European Liver Transplant Registry
*Purpose: Little is known about combined hepatocellular-cholangiocarcinoma (cHCC-CCA) demographics and their long-term outcomes after liver transplantation (LT). By analysing data from the European Liver Transplant…2022 American Transplant Congress
Degree of Pre-Liver Transplant Immune Dysfunction Correlates with Post-Transplant Cancer Recurrence
1Rutgers New Jersey Medical School, Newark, NJ, 2Houston Methodist Hospital, Houston, TX
*Purpose: Despite stringent selection criteria for liver transplant (LT) in patients with liver-limited malignancy, post-transplant cancer recurrence remains problematic. We have previously identified a pre-LT…2022 American Transplant Congress
Use of Targeted T-Cell Therapy (Posoleucel) for the Treatment of Epstein-Barr Virus Associated Leiomyosarcoma in an Adult Kidney Transplant Recipient: A Case Report
*Purpose: Epstein-Barr virus (EBV)-associated leiomyosarcomas (EBV+LMS) are neoplasms rarely seen in solid organ transplant (SOT) recipients and currently lack effective treatment options. We present a…2022 American Transplant Congress
Increased Regulatory T-cells in Tumor Microenvironment is Associated with Hepatocellular Carcinoma Differentiation in Patients Undergoing Liver Transplantation
1Surgery, University of Kentucky, Lexington, KY, 2UKHC, Lexington, KY
*Purpose: Tumor-infiltrating lymphocytes are an essential component of the tumor microenvironment. The balance between cytotoxic effector T cells and immunosuppressive regulatory T cells is critical…2022 American Transplant Congress
Establishing a New Hepatobiliary Surgery Program in a Level 1 Trauma Center Community Teaching Hospital (Our Open and Robotic Experience)
General Surgery, St. Elizabeth Youngstown Hospital, Youngstown, OH
*Purpose: To improve access to quality care, the surgical outcomes and influencing factors were investigated for a new hepatobiliary surgery program established by a transplant…2022 American Transplant Congress
Is Repeat Resection for Recurrent Intrahepatic Cholangiocarcinoma Warranted? Outcomes of an International Multicenter Analysis
*Purpose: Recurrence of intrahepatic cholangiocarcinoma (ICC) after liver resection (LR) remains high and optimal therapy for recurrent ICC is challenging. Herein we assess the outcomes…2022 American Transplant Congress
De Novo Fibrinogen Alpha Chain Amyloidosis in Kidney Allograft
*Purpose: Amyloidosis is a disorder characterized by tissue deposition of misfolded proteins that can lead to organ damage such as renal failure. There are multiple…
- 1
- 2
- 3
- …
- 20
- Next Page »